PROVO, Utah, Feb. 21, 2012 /PRNewswire/ --Nu Skin Enterprises Inc., (NYSE: NUS) today announced the conclusion of another banner year for its ageLOC® research. Nu Skin accelerated its anti-aging research in 2011 with more than 30 scientific presentations, posters and articles at various prestigious conferences and symposia around the world. Additionally, the company made further strides with the acquisition of LifeGen Technologies and its genetic database that is based on more than 30 years of anti-aging genetic research.
"2011 was a breakthrough year for us as we continued our ground-breaking ageLOC anti-aging genetic research that is opening new doors of understanding to the genetic source of aging and helping more people to live younger, longer," said Joe Chang, Ph.D., Nu Skin chief scientific officer. "As we have presented our research around the world, we have been pleased with the favorable response we have received from the scientific community. Looking to 2012, we believe that the best is yet to come for ageLOC science."
The company's 2011 scientific presentations focused on its ageLOC science that enables Nu Skin to identify unique groups of genes specific to aging (referred to as Youth Gene Clusters or YGC) that influence aging and then target and reset them to more youthful patterns of activity. This latest scientific research has been incorporated into Nu Skin's latest product releases including ageLOC® R2 (R-squared) and ageLOC® Galvanic Body Spa'.
2011 Scientific Highlights Include:
Acquisition of LifeGen Technologies, LLC
With the acquisition of LifeGen Technologies, Nu Skin now owns what it believes is one of the largest anti-aging databases in the world and has unrestricted access to LifeGen's scientific data and findings developed over 30 years. Nu Skin is accelerating its anti-aging genetic research that continues to open doors of new understanding and is providing additional insights for product development. Already the company has felt the positive impact of this database as it incorporates these new insights into products under development for 2013, including solutions for weight management and overall youthspan.
ageLOC Research on Internal Aging
Mark Barlett, Ph.D., vice president of global research and development for Pharmanex nutrition products at Nu Skin, led his team to present several key findings at internationally recognized conferences. Highlights included being an invited speaker at the Second International Conference on Environmental Stressors in Biology and Medicine. Nu Skin presented findings on several topics at the conference including "A Unique Nutritional Formulation to Promote Cellular Protection and Purification Via Induction Of the Nrf2-mediated ARE/Phase II Detoxification Pathways" and "A Unique Blend of Natural Compounds With the Ability to Oppose Age-Related Changes in Gene Expression Related to Dysregulation of Removal of Cellular Debris, Cellular Detoxification, Antioxidant Protection and Inflammatory Balance."
In addition, Pharmanex nutrition scientists also presented at the Linus Pauling Institute Diet and Optimum Health Conference on "A Systematic Approach to Evaluate and Rank Natural Ingredients Based on Their Ability to Oppose Age-Related Changes in Gene Expression."
ageLOC Research on the Skin
Led by Helen Knaggs, Ph.D., vice president of global research and development for Nu Skin personal care products, the Nu Skin research and development team had several notable finding presented and published in 2011. An oral presentation shared at the 4th International Conference and Exhibition for Nutraceuticals and Functional Foods (Nov 2011) showed the effects of equol on human skin gene expression and protein synthesis. In addition, several scientific articles were published including one in the Dermatological Surgery (Dec. 2011), regarding an exploratory study to determine the association between assessed facial skin aging and plasma isoprostane levels in middle-aged Japanese women, and in the International Journal of Cosmetic Science (Feb. 2011) showing how functional YGCs can be regulated to reflect a more youthful gene expression profile.
New Patents for ageLOC® Galvanic Body Spa'
Throughout the development of ageLOC science, a number of patents have been licensed or filed to further protect the proprietary information and technology Nu Skin utilizes to develop ageLOC branded products. Nu Skin's recently launched ageLOC® Galvanic Body Spa' system uses patented self-adjusting galvanic currents with patent-pending pulsating technology to diminish the appearance of fat and cellulite to provide a slimmer, smoother, firmer appearance on the arms, abdomen, buttocks and thighs.
Additional information on ageLOC Science can be found at http://www.ageloc.com.
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its unique ageLOC® science that addresses aging at its source. The company's anti-aging products feature the new ageLOC ® suite of products including the ageLOC® R2 (R-squared) nutritional supplement, ageLOC® Galvanic Spa System and ageLOC Galvanic Body Spa', as well as the ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 52 markets worldwide and has more than 850,000 independent distributors. Nu Skin is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskin.com.
Please note: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the company's current expectations and beliefs regarding the company's research and development efforts and the company's other plans and strategies. These forward-looking statements are based on current information and expectations, and are subject to risks and uncertainties discussed in company filings with the U.S. Securities and Exchange Commission, which could cause the company's actual results to differ materially from expected results. The company undertakes no obligation to publicly update any forward-looking statement contained in this press release, whether as a result of new information, future developments or otherwise, except as may be required by law.
SOURCE Nu Skin Enterprises, Inc.
